NetworkNewsBreaks – Cybin Inc. (NYSE American: C
Post# of 341
Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a panel discussion titled “Trials to Treatments” at the Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event in Haarlem, Amsterdam. The announcement includes further details on additional conferences and the participation schedule for Drysdale and additional members of Cybin’s management team in panel discussions and presentations. The additional events include the Interdisciplinary Conference on Psychedelic Research, Sept. 22-24, 2022, in Haarlem, Amsterdam, Jefferies Innovation in Mental Health Summit, Sept. 22, 2022, in New York City, New York, and the Cantor Neurology & Psychiatry Conference, Oct. 6-7, 2022, in San Francisco, California.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer